Research programme: gonadotrophin releasing hormone antagonists - AbbVie/NeurocrineAlternative Names: GnRH antagonists - Neurocrine Biosciences
Latest Information Update: 05 Feb 2013
At a glance
- Originator Neurocrine Biosciences
- Developer AbbVie; Neurocrine Biosciences
- Class Diamines
- Mechanism of Action Gonadotropin releasing hormone inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
- No development reported Benign prostatic hyperplasia